acetyl cysteine (NAC) augmentation in Obsessive-Compulsive Disorder (OCD): A 24-week, randomized, double blind placebo controlled trial

The University of Melbourne0 个研究点目标入组 98 人开始时间: 2016年6月29日最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Primary diagnosis of OCD as per the Structured Interview Guide for the DSM-5 (SCID)
•Adults between the age of 18-75 who have the desire and capacity to consent to the study and follow its procedures.
•Minimum score of 16 on the Y-BOCS at time of entry into the study, but no greater than 31.
•Currently taking medication for their OCD which has been at a stable dose for the past 8-weeks.
•Stable psychological treatment (if employing) for minimum eight weeks (an 8-week wash-out period will be required if participants have just completed an intensive in-patient CBT program for their OCD).

•*Bipolar disorder
•*Psychotic disorders
•*Primary diagnosis of Obsessive-compulsive spectrum disorders including hoarding, body dysmorphic disorder, trichotillomania (secondary diagnosis permitted)
•*Severe depression (as defined by HAM-D score equal to or greater than 24
•*Alcohol/substance abuse
•*Y-BOCS score equal to or greater than 32
•*Treatment resistant OCD (3 or more trials of first line medications for their OCD at therapeutic doses for minimum of 12-weeks each, at least one augmentation strategy, for example, anti psychotic medication as well as exposure response prevention therapy minimum 20 hours)
•*Medications with known or suspected negative interactions with NAC (activated charcoal, nitro glycerine, insulin replacement therapies, Aralen, anti-coagulant medications excluding aspirin and NSAIDS)

发起方